Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.71	7.47	9.11	12.96	3.18
Cash & Short-Term Investments	3.71	7.47	9.11	12.96	3.18
Cash Growth	-50.41%	-17.97%	-29.69%	308.10%	27.87%
Other Receivables	0.05	0.13	-	-	-
Receivables	0.05	0.13	-	-	-
Prepaid Expenses	0.1	0.11	0.26	0.3	0.05
Total Current Assets	3.86	7.71	9.38	13.25	3.22
Total Assets	3.86	7.71	9.38	13.25	3.22
Accounts Payable	0	0	0.03	0.06	-
Accrued Expenses	3.24	3.04	2.03	0.78	0.46
Current Portion of Long-Term Debt	-	-	-	-	0.02
Total Current Liabilities	3.24	3.04	2.06	0.84	0.47
Long-Term Debt	-	-	-	-	0.05
Total Liabilities	3.24	3.04	2.06	0.84	0.52
Common Stock	0.02	0.01	0.01	0.01	16.5
Additional Paid-In Capital	67.92	57.87	45.94	38.95	-
Retained Earnings	-67.32	-53.22	-38.64	-26.55	-13.8
Shareholders' Equity	0.62	4.67	7.32	12.41	2.7
Total Liabilities & Equity	3.86	7.71	9.38	13.25	3.22
Total Debt	-	-	-	-	0.07
Net Cash (Debt)	3.71	7.47	9.11	12.96	3.11
Net Cash Growth	-50.41%	-17.97%	-29.69%	316.83%	25.19%
Net Cash Per Share	0.23	0.59	0.84	1.52	0.50
Filing Date Shares Outstanding	22.04	15.76	11.64	10.23	13.59
Total Common Shares Outstanding	17.03	14.47	11.63	10.22	13.59
Working Capital	0.62	4.67	7.32	12.41	2.75
Book Value Per Share	0.04	0.32	0.63	1.21	0.20
Tangible Book Value	0.62	4.67	7.32	12.41	2.7
Tangible Book Value Per Share	0.04	0.32	0.63	1.21	0.20

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q